Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06215222 · ClinicalTrials.gov registry record

Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease

A clinical trial of Healthy and IBS - Irritable Bowel Syndrome, sponsored by Stanford University.

Recruiting
Registry status
40
Enrollment target
1
Study location

NCT06215222 is a study of Healthy and IBS - Irritable Bowel Syndrome that is actively recruiting participants, run by Stanford University. The registered enrollment target is 40 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06215222, a study of Healthy and IBS - Irritable Bowel Syndrome, is actively recruiting participants, sponsored by Stanford University.

RECRUITING
Registry status
40 participants
Enrollment target
1
Study location

Study Summary

We will sample intestinal microbiota using a microbiome sampling capsule in Healthy, Irritable Bowel Syndrome (IBS), and Functional Gastrointestinal Disease.

Interventions

  • OTHER Microbiota Sampling

Study Locations (1)

California

  • Stanford Digestive Health Clinic - Redwood City

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-11-16
Est. Completion 2026-12-01

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT06215222

The ClinicalTrials.gov registry entry for NCT06215222 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (94% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which Microbiota Sampling is the first listed.

NCT06215222 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT06215222 about?

NCT06215222 is a clinical study titled "Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease". We will sample intestinal microbiota using a microbiome sampling capsule in Healthy, Irritable Bowel Syndrome (IBS), and Functional Gastrointestinal Disease.

What is the current status of trial NCT06215222?

This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2023-11-16. Estimated completion is 2026-12-01.

What conditions does trial NCT06215222 study?

This clinical trial studies the following conditions: Healthy, IBS - Irritable Bowel Syndrome, Functional Gastrointestinal Disorders, Functional Bloating.

What interventions are being tested in trial NCT06215222?

The interventions under investigation include: Microbiota Sampling (OTHER).

Who is sponsoring clinical trial NCT06215222?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06215222 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.